FDA Grants Approval for Flecainide Acetate by OMSAV Pharma
The FDA has granted approval for Flecainide Acetate under application ANDA218093 submitted by OMSAV Pharma.
Published: July 28, 2026
Updated: July 28, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiology / Antiarrhythmic
Company: OMSAV Pharma
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
OMSAV Pharma
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Flecainide Acetate by OMSAV Pharma is significant as it strengthens their competitive position in the antiarrhythmic market. This development may lead to shifts in market dynamics, prompting other companies to respond strategically.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market uptake and any competitive responses from other antiarrhythmic drug manufacturers.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.